Background Colon capsule endoscopy (CCE) emerged as a promising alternative for lower gastrointestinal (GI) investigation, particularly during the COVID-19 pandemic. However, its adoption remains ...

Objective The association between baseline pretreatment serum HBV DNA levels and on-treatment hepatocellular carcinoma (HCC) risk remains controversial in patients with chronic hepatitis B (CHB). We ...

Objective Alcoholic hepatitis (AH) reflects acute exacerbation of alcoholic liver disease (ALD) and is a growing healthcare burden worldwide. Interleukin-11 (IL-11) is a profibrotic, proinflammatory ...

Background GPR171 suppresses T cell immune responses involved in antitumour immunity, while its role in inflammatory bowel disease (IBD) pathogenesis remains unclear. Objective We aimed to investigate ...

With great interest, we have read the article by Clooney et al , which highlighted the regional effects on the heterogeneity of the gut microbiota among populations with inflammatory bowel disease ...

Pharmacological activation of STAT1-GSDME pyroptotic circuitry reinforces epigenetic immunotherapy for hepatocellular carcinoma ...

We read with great interest the study by Digby et al , which presents an innovative approach towards improving colorectal cancer (CRC) risk stratification by combining faecal haemoglobin (f-Hb), ...

Objective Since the publication of the first Asia Pacific Consensus on Colorectal Cancer (CRC) in 2008, there are substantial advancements in the science and experience of implementing CRC screening.

Introduction There is a higher prevalence of autoimmune thyroid disease (AITD) in patients with coeliac disease. Therefore, current NICE guidelines recommend patients with AITD should be screened for ...

Background Intestinal fibrosis resulting in stricture formation and obstruction in Crohn’s disease (CD) and increased wall stiffness leading to symptoms in ulcerative colitis (UC) is among the largest ...

Introduction Eosinophilic oesophagitis (EoE) is a chronic, immune-mediated condition characterized by eosinophilic infiltration of the oesophagus, leading to symptoms such as dysphagia and food bolus ...

Objective Phase II trials suggest glucagon-like peptide-1 receptor (GLP1) agonists resolve metabolic dysfunction-associated steatohepatitis but do not affect fibrosis regression. We aimed to determine ...